You're contacting media contact of this press release
Title: Neuralia TMS Breaks Down TMS Therapy Cost and Insurance Options
Australia, 20th Nov 2026 - Neuralia TMS, a specialist provider of transcranial magnetic stimulation (TMS) in Perth, Western Australia, has announced a plain breakdown of how funding works for patients considering TMS therapy, covering Medicare, referrals and private health insurance. According to the company, the explanation sets out which parts of a course are funded, which are not, and where patients are asked to confirm their circumstances before booking.Neuralia TMS provides a non-invasive form of brain stimulation (link pending) in a specialised TMS suite, the company said. TMS uses an electromagnetic coil placed against the scalp to deliver magnetic pulses, and treatment is arranged as a course of sessions rather than a single visit. The company also offers transcranial direct current stimulation, known as tDCS, and pharmacogenetic testing, with clinics in Como, Kardinya and Armadale.What the Announcement Means for Medicare PatientsMedicare is Australia’s public health insurance scheme, and some services attract a Medicare rebate when set criteria are met. According to Neuralia TMS, most patients on an initial Medicare-funded course pay $0 out of pocket for TMS at the clinic. The company states that Medicare covers up to 35 sessions in an initial course, and that a course is typically delivered five times a week over four to six weeks.“Patients should be able to see what Medicare funds and what it does not before they book,” said Dr Shanek Wick, Medical Director of Neuralia TMS. “Eligibility depends on each person’s history, which is why the clinic asks patients to check their circumstances with the team.”The company also states that a rebate applies only when every eligibility requirement is met. Previous TMS in any setting rules out the initial-course Medic...
This press release is issued by King Newswire